Fresenius Medical Care (FME) Received a €96.00 Target Price at Credit Suisse Group

Fresenius Medical Care (FME) Received a €96.00 Target Price at Credit Suisse Group

Other research analysts also recently issued research reports about the company. DZ Bank set a €107.00 ($127.38) price objective on Fresenius Medical Care and gave the stock a buy rating in a research note on Wednesday, January 31st. Berenberg Bank set a €101.00 ($120.24) price objective on Fresenius Medical Care and gave the stock a buy rating in a research note on Tuesday, February 13th. Citigroup set a €92.00 ($109.52) price objective on Fresenius Medical Care and gave the stock a buy rating in a research note on Monday, February 12th. JPMorgan Chase set a €95.60 ($113.81) price objective on Fresenius Medical Care and gave the stock a buy rating in a research note on Tuesday, February 27th. Finally, Goldman Sachs set a €97.00 ($115.48) price objective on Fresenius Medical Care and gave the stock a buy rating in a research note on Tuesday, February 27th. Eight investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Fresenius Medical Care has an average rating of Buy and an average price target of €93.09 ($110.82).

Credit Suisse Group set a €96.00 ($114.29) target price on Fresenius Medical Care (ETR:FME) in a report released on Tuesday morning. The brokerage currently has a buy rating on the stock.

ETR FME opened at €84.60 ($100.71) on Tuesday. Fresenius Medical Care has a 52 week low of €75.53 ($89.92) and a 52 week high of €93.82 ($111.69).

Fresenius Medical Care Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.

Related posts

Leave a Comment